Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 29 of 40, showing 5 Applications out of 196 total, starting on record 141, ending on 145

# Protocol No Study Title Investigator(s) & Site(s)

141.

ECCT/21/07/03   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Prof Jessie N Githanga
2. Fredrick Sirwa Chite
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
View

142.

ECCT/21/11/08   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Videlis N Nduba
2. Prof. Jessie N Githanga
3. Fredrick Sirwa Chite
4. Bernhards Ragama Ogutu
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
3. Gertrude’s Children’s Hospital. (Nairobi City county)
4. Strathmore University Medical Centre (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
View

143.

ECCT/21/11/04   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Prof Jessie N Githanga
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
View

144.

ECCT/21/12/05   131 Inclacumab Ph 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N Nduba
4. Prof. Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
View

145.

ECCT/24/08/06   KALUMA Study
    A randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥ 5 kg body weight followed by an Extension phase with repeated KLU156 treatment    
Principal Investigator(s)
1. Dr Patricia Odera Ojwang
2. Dr. Bernhards Ogutu
3. Dr.Bernhards Ogutu
Site(s) in Kenya
1. Site 1600: Kenya Medical Research Institute/Centre for Global Health Research Siaya (Siaya county)
2. Site 1601:Kombewa Clinical Research Centre (Kisumu county)
3. Ahero Clinical Trial Unit (Kisumu county)
 
View